Abstract

Although the expression of co-stimulatory molecules plays an important role in the immune system, only little is known about their regulation in dementias. Therefore, we determined the expression of CD28, ICOS (CD278) and CTLA-4 (CD152) by CD4 + and CD8 + T cells in the peripheral blood of patients with mild cognitive impairment (MCI; N = 19), Alzheimer’s disease (AD; N = 51), vascular dementia (VD; N = 21) and frontotemporal dementia (FTD; N = 6) at the point in time of diagnosis compared to 19 non-demented elderly persons. The expression of CD28 and ICOS by CD4 + and CD8 + T cells was not changed in AD, FTD or VD patients. The expression of the negative regulator CTLA-4 was increased by CD4 + T cells from AD and FTD patients and by CD8 + T cells from VD patients. The classification of the AD patients according to the severity of the disorder showed stage-dependent alterations of CD28, ICOS and CTLA-4 expression. In AD patients, the correlation analysis showed an association between the decline in CD28 + T cells and the increase in CTLA-4 + T cells with cognitive decline, measured by the mini-mental state examination (MMSE), tau proteins and Amyloid-β, important AD biomarkers in cerebrospinal fluid (CSF). In FTD patients, a positive association between Q Albumin, a marker for blood-CSF-barrier function, and CD28 and a negative correlation between Q Albumin and ICOS expression were determined. Our data suggest a dysregulated balance between the expression of negative and positive co-stimulatory molecules by T cells in AD patients, which might contribute to chronic inflammation observed in dementia.

Highlights

  • IntroductionIn 2010, approximately 35.6 million people worldwide suffered from dementia, a number which is expected to triple by the year 2050

  • In our aging population, the prevalence of dementia is increasing

  • Using flow cytometry of peripheral whole blood, we analyzed the frequency of CD4 + and CD8 + T cells and the expression of CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inducible T cell co-stimulator (ICOS) in patients suffering from Alzheimer’s disease (AD), vascular dementia (VD) and frontotemporal dementia (FTD) and compared them to non-demented controls

Read more

Summary

Introduction

In 2010, approximately 35.6 million people worldwide suffered from dementia, a number which is expected to triple by the year 2050. 7.7 million people were newly diagnosed with dementia worldwide. The most prevalent cause of dementia is Alzheimer’s disease (AD). Vascular dementia (VD) and frontotemporal dementia (FTD) contribute to the loss of cognitive functions and behavioural changes in elderly people [1,2,3,4]. In AD, Amyloid-β1-42, and tau proteins are established core

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call